[Development of antibodies for immunotherapy of Alzheimer's disease].

Rinsho Shinkeigaku

Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University.

Published: April 2014

Based on the amyloid cascade hypothesis, immunotherapy targeting amyloid β (Aβ) for Alzheimer's disease (AD) has been developed. It was reported that active immunization using Aβ peptide attenuates amyloid deposits and memory impairment in AD model mice. However, active immunization of patients with AD (AN-1792) was halted due to adverse effects in which a subset of patients developed meningoencephalitis. In order to avoid autoimmune encephalitis, passive immunotherapy using humanized monoclonal antibodies with specificity to Aβ are in clinical trials. We also developed an anti-Aβ monoclonal antibody 3.4A10, which react with AD brain-specific Aβ oligomers. On the other hand, some studies showed that immunotherapy approach targeting tau could attenuate pathology in AD model mouse. Here we introduce a current trend of immunotherapy for AD.

Download full-text PDF

Source
http://dx.doi.org/10.5692/clinicalneurol.52.1168DOI Listing

Publication Analysis

Top Keywords

active immunization
8
immunotherapy
5
[development antibodies
4
antibodies immunotherapy
4
immunotherapy alzheimer's
4
alzheimer's disease]
4
disease] based
4
based amyloid
4
amyloid cascade
4
cascade hypothesis
4

Similar Publications

Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.

View Article and Find Full Text PDF

Background: Maternal tetanus toxoid (MTT) vaccination during pregnancy remains an important factor for reducing infant mortality globally, especially in developing nations, including Bangladesh. Despite commendable progress in reducing child mortality through widespread MTT vaccination during pregnancy, the issue still exists. This analysis explores the impact of MTT vaccination on neonatal mortality in Bangladesh and identifies associated factors.

View Article and Find Full Text PDF

Anti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens.

Sci Immunol

January 2025

Department of Integrative, Structural and Computational Biology, Scripps Research, La Jolla, CA, USA.

Vaccination strategies against HIV-1 aim to elicit broadly neutralizing antibodies (bnAbs) using prime-boost regimens with HIV envelope (Env) immunogens. Epitope mapping has shown that early antibody responses are directed to easily accessible nonneutralizing epitopes on Env instead of bnAb epitopes. Autologously neutralizing antibody responses appear upon boosting, once immunodominant epitopes are saturated.

View Article and Find Full Text PDF

Computational approaches of modelling human papillomavirus transmission and prevention strategies: a systematic review.

J Biol Dyn

December 2025

Modelling and Simulation Research Group, School of Computer Science, Faculty of Engineering, The University of Sydney, Sydney, NSW, Australia.

Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the world. Persistent oncogenic HPV infection has been a leading threat to global health and can lead to serious complications such as cervical cancer. Prevention interventions including vaccination and screening have been proven effective in reducing the risk of HPV-related diseases.

View Article and Find Full Text PDF

Protocol for evaluating humoral immune responses in mice following SARS-CoV-2 vaccination.

STAR Protoc

January 2025

Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China; State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China. Electronic address:

Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!